Stock Track | Novo-Nordisk Shares Plummet 5.27% on Fears of Slowdown in GLP-1 Drug Sales

Stock Track

Jan 15, 2025

Shares of Danish pharmaceutical giant Novo-Nordisk A/S experienced a significant 5.27% drop on Tuesday intraday trading session, amid concerns over a potential slowdown in the sales growth of its blockbuster GLP-1 diabetes and weight-loss drugs.

The stock plunge was triggered by news from rival company Eli Lilly, which warned that its fourth-quarter 2024 revenue from the GLP-1 drug market (known as the "incretin market") is expected to be approximately $400 million lower than previously anticipated. While Eli Lilly's overall sales for 2024 and 2025 still showed strong growth, the potential slowdown in the lucrative GLP-1 segment raised concerns among investors.

Analysts speculate that Novo-Nordisk, as a key player in the GLP-1 market, could be impacted by this slowdown, leading to a sell-off in its shares. Notably, Eli Lilly stated that it did not gain any additional market share in the fourth quarter of 2024, implying that Novo-Nordisk's market position remained stable during that period.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1193617757"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1193617757\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1193617757?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-15 01:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1193617757","market":"hk","top_or_hot":-1,"title":"Stock Track | Novo-Nordisk Shares Plummet 5.27% on Fears of Slowdown in GLP-1 Drug Sales","media":"Stock Track","content":"<p>Shares of Danish pharmaceutical giant Novo-Nordisk A/S experienced a significant 5.27% drop on Tuesday intraday trading session, amid concerns over a potential slowdown in the sales growth of its blockbuster GLP-1 diabetes and weight-loss drugs.</p>\n\n<p>The stock plunge was triggered by news from rival company Eli Lilly, which warned that its fourth-quarter 2024 revenue from the GLP-1 drug market (known as the \"incretin market\") is expected to be approximately $400 million lower than previously anticipated. While Eli Lilly's overall sales for 2024 and 2025 still showed strong growth, the potential slowdown in the lucrative GLP-1 segment raised concerns among investors.</p>\n\n<p>Analysts speculate that Novo-Nordisk, as a key player in the GLP-1 market, could be impacted by this slowdown, leading to a sell-off in its shares. Notably, Eli Lilly stated that it did not gain any additional market share in the fourth quarter of 2024, implying that Novo-Nordisk's market position remained stable during that period.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Novo-Nordisk Shares Plummet 5.27% on Fears of Slowdown in GLP-1 Drug Sales</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Novo-Nordisk Shares Plummet 5.27% on Fears of Slowdown in GLP-1 Drug Sales\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-01-15 01:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Danish pharmaceutical giant Novo-Nordisk A/S experienced a significant 5.27% drop on Tuesday intraday trading session, amid concerns over a potential slowdown in the sales growth of its blockbuster GLP-1 diabetes and weight-loss drugs.</p>\n\n<p>The stock plunge was triggered by news from rival company Eli Lilly, which warned that its fourth-quarter 2024 revenue from the GLP-1 drug market (known as the \"incretin market\") is expected to be approximately $400 million lower than previously anticipated. While Eli Lilly's overall sales for 2024 and 2025 still showed strong growth, the potential slowdown in the lucrative GLP-1 segment raised concerns among investors.</p>\n\n<p>Analysts speculate that Novo-Nordisk, as a key player in the GLP-1 market, could be impacted by this slowdown, leading to a sell-off in its shares. Notably, Eli Lilly stated that it did not gain any additional market share in the fourth quarter of 2024, implying that Novo-Nordisk's market position remained stable during that period.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVO","symbol_name":"诺和诺德","start_time":0,"source_url":"","article_id":"1193617757","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1193617757","pubTimestamp":1736875107,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Danish pharmaceutical giant Novo-Nordisk A/S experienced a significant 5.27% drop on Tuesday intraday trading session, amid concerns over a potential slowdown in the sales growth of its blockbuster GLP-1 diabetes and weight-loss drugs.The stock plunge was triggered by news from rival company Eli Lilly, which warned that its fourth-quarter 2024 revenue from the GLP-1 drug market  is expected to be approximately $400 million lower than previously anticipated. While Eli Lilly's overall sa","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVO":"诺和诺德"},"translate_title":"股票轨迹诺和诺德股价暴跌5.27%，因担心GLP-1药物销售放缓","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1},"content_text":"Shares of Danish pharmaceutical giant Novo-Nordisk A/S experienced a significant 5.27% drop on Tuesday intraday trading session, amid concerns over a potential slowdown in the sales growth of its blockbuster GLP-1 diabetes and weight-loss drugs.\nThe stock plunge was triggered by news from rival company Eli Lilly, which warned that its fourth-quarter 2024 revenue from the GLP-1 drug market (known as the \"incretin market\") is expected to be approximately $400 million lower than previously anticipated. While Eli Lilly's overall sales for 2024 and 2025 still showed strong growth, the potential slowdown in the lucrative GLP-1 segment raised concerns among investors.\nAnalysts speculate that Novo-Nordisk, as a key player in the GLP-1 market, could be impacted by this slowdown, leading to a sell-off in its shares. Notably, Eli Lilly stated that it did not gain any additional market share in the fourth quarter of 2024, implying that Novo-Nordisk's market position remained stable during that period.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}